Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for PF-03882845

See Plans and Pricing

« Back to Dashboard

What is the drug development status for PF-03882845?

PF-03882845 is an investigational drug.

There have been 5 clinical trials for PF-03882845. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Kidney Diseases, and Diabetic Nephropathies. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are two US patents protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for PF-03882845
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic NephropathyPfizerPhase 1
Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin PharmacokineticsPfizerPhase 1
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy VolunteersPfizerPhase 1

See all PF-03882845 clinical trials

Clinical Trial Summary for PF-03882845

Top disease conditions for PF-03882845
Top clinical trial sponsors for PF-03882845

See all PF-03882845 clinical trials

US Patents for PF-03882845

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-03882845   Start Trial Pyrazoline compounds Pfizer Inc. (New York, NY)   Start Trial
PF-03882845   Start Trial Pharmaceutical compositions for preventing glucocorticoid-induced skin thinning INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE PARIS DESCARTES (Paris, FR) UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6) (Paris, FR) ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (Paris, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-03882845

Drugname Country Document Number Estimated Expiration Related US Patent
PF-03882845 African Regional IP Organization (ARIPO) 2527 2026-10-31   Start Trial
PF-03882845 Argentina 063529 2026-10-31   Start Trial
PF-03882845 Austria 537151 2026-10-31   Start Trial
PF-03882845 Australia 2007315884 2026-10-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.